China Lung Cancer Therapeutics Market Report 2022 to 2030

China Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the China Lung Cancer Therapeutics Market will reach a value of $5 Bn from $2.4 Bn in 2022, growing at a CAGR of 9.6% during 2022-2030. The Lung Cancer Therapeutics Market in China is dominated by a few domestic pharmaceutical companies such as BeiGene, Jiangsu Hengrui Medicine, and Hutchison. The Lung Cancer Therapeutics Market in China is segmented into different types of cancer and different therapy type. Some of the major factors affecting the China lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10CNPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Dr. Vishwa Modhia

Buy Now

China Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the China Lung Cancer Therapeutics market will reach a value of $5 Bn from $2.4 Bn in 2022, growing at a CAGR of 9.6% during 2022-2030.

China is an upper middle-income developing country in East Asia bordering the East China Sea, Korea Bay, and the South China Sea. Lung cancer ranked top in China in terms of both incidence and death rate, with 820,000 new cases and 710,000 deaths recorded in 2020. China has made significant progress in the treatment of lung cancer over the last decade, particularly in targeted therapy, which is the foundation of precision medicine that "targets" cancer cells without hurting normal cells.

According to the latest WHO data published in 2020 Lung Cancers Deaths in China reached 714,311 or 7.44% of total deaths. The age-adjusted Death Rate is 36.63 per 100,000 population ranks China 5^th in the world. China's government spends 5.6% of its GDP on healthcare.

China Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

China has achieved significant advances in the diagnosis and treatment of lung cancer, which is the leading cause of death in the country and around the world. Manufacturing is highly valued in China, while the services industry is growing as a result of e-commerce trends. In China, lung cancer patients are increasingly being treated using minimally invasive surgery, particularly thoracoscopy, which causes far less harm to the body than open surgery did in the past. These aspects could boost China's Lung Cancer Therapeutics market.

Market Restraints

Immunotherapy was previously lagging in China, but there is now a rush of immunotherapeutic medications under development. Because of its increasing incidence and high mortality, lung cancer is a major public health issue and a huge burden on society in China. In China, several unique gene profiles were linked to lung cancer. The local Chinese Society of Clinical Oncology Guidelines, which take drug accessibility and regional development disparities into account, is highly recommended for clinical practice. These factors may deter new entrants into the China Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

BeiGene: BeiGene is a Chinese biotechnology company that produces several drugs for the treatment of lung cancer, including Tislelizumab and Pamiparib
Jiangsu Hengrui Medicine: Jiangsu Hengrui Medicine is a Chinese pharmaceutical company that produces several drugs for the treatment of cancer, including lung cancer
Innovent Biologics: Innovent Biologics is a Chinese biopharmaceutical company that produces several drugs for the treatment of lung cancer, including Tyvyt and Sintilimab
Hutchison China MediTech (Chi-Med)
Shanghai Junshi Biosciences
Fosun Pharma
Sinopharm

Recent Notable Updates

January 2023: HUTCHMED (China) announced that ORPATHYS (savolitinib) has been added to the updated National Reimbursement Drug List (NRDL) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patients with MET exon 14-skipping alterations who have progressed after or are unable to tolerate platinum-based chemotherapy. The revised NRDL will go into effect on March 1, 2023. Savolitinib, sold in China as ORPATHYS, is an oral, powerful and highly selective MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and HUTCHMED, with HUTCHMED assuming the lead in China, and commercialised globally by AstraZeneca.

Healthcare Policies and Reimbursement Scenarios

Different agencies, such as the National Medical Products Administration (NMPA), the Chinese National Health Commission (NHC), and the Chinese healthcare system, oversee and reimburse lung cancer therapies in China. The NMPA oversees regulating and approving lung cancer therapies in China. The Chinese healthcare system oversees reimbursing NHC-recommended lung cancer therapies. Also, some carcinoma medicines may be offered through specific initiatives inside the Chinese healthcare system, such as the National Reimbursement Drug List, which offers funds for cancer treatments that are not readily accessible.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.